TLR4 and cervical carcinoma: Multiple TLR4 activators have been studied in experimental and clinical trials, including AS04 (FDA-approved for cervical cancer), MPLA (derivative of lipid A, cervical cancer), and GLA-SE (G100-synthetic GLA, lymphoma tumor) [71, 72].